Type 1 diabetes (with predominant insulin de ciency) was until recently assumed to be the diagnosis of almost all children presenting with glucose intolerance. This requires insulin treatment via subcutaneous injections, and most patients develop microvascular and macrovascular complications in adulthood. Advances in genetics in the 1990s identi ed a group of genetic disorders of pancreatic b-cell function (maturity-onset diabetes of the young) for which the outlook is better than type 1, genetic testing is available, and oral medication is the preferred treatment. In 2000, the rst cases of type 2 diabetes (predominant insulin resistance) were reported in UK children, re ecting a trend seen in North America over the last 20 years. Affected children are usually overweight or obese, often female, pubertal, predominantly of ethnic minority (South Asian) origin and have a family history of type 2 diabetes. The diagnosis is aided by demonstration of insulin resistance, and may include measurement of fasting insulin and C-peptide, markers of the metabolic syndrome (fasting lipids, sex hormone binding globulin) and absence of autoantibodies against b-cell components (e.g. glutamic acid decarboxylase). Management is aimed towards weight stabilization in the growing child, education on healthy lifestyles and the treatment of hyperglycaemia with both insulin and insulin-sensitizing agents. The underlying cause of type 2 diabetes in children is likely to be related to the epidemic of childhood obesity. There is emerging evidence of an appalling outlook for these young people in terms of miscarriages and microvascular and cardiovascular complications, which are likely to present an enormous economic and health services burden over the next 20 years.
Introduction
Diabetes is the third most common chronic disease in childhood, a¡ecting one in 400 UK children; the vast majority of children have type 1 or insulin-dependent diabetes. The diagnosis is based on clinical signs, with the only biochemical investigation often being the demonstration of an elevated plasma glucose. Recent advances in genetics have identi¢ed rarer subtypes of diabetes (maturity-onset diabetes of the young, MODY) that may require oral treatment and for which genetic testing is appropriate. Most recently, type 2 diabetes has been described in children, in which the predominant defect is insulin resistance. Type 2 diabetes poses a diagnostic challenge, as many of the clinical and biochemical signs overlap those of type 1 diabetes, yet the clinical management is di¡erent. This review focuses on the emergence of type 2 diabetes in childhood, the biochemical investigations that may be appropriate and the outlook for children compared with adults with this condition.
Over 95% of childhood diabetes is type 1, caused by autoimmune destruction of the insulin-producing islets in the pancreas. The principal abnormality is absolute insulin de¢ciency, requiring lifelong insulin treatment. The incidence of type 1 diabetes has been rising for at least 30 years, with the fastest rise occurring in the under 5 years old age group. 1 The diagnosis is made on clinical grounds and the demonstration of a raised plasma glucose. About 40% of children present with some evidence of ketone production or diabetic ketoacidosis; these children also require assessment of acid-base status. Antibodies to glutamate decarboxylase are demonstrable in over 85% of newly presenting children, but are not usually necessary for the diagnosis. The importance of correctly diagnosing type 1 diabetes lies in its absolute insulin dependence and high mortality without insulin treatment.
The predominant defect in type 2 diabetes is peripheral resistance to the e¡ects of insulin, with a variable insulin secretory defect. Insulin resistance occurs when there is target tissue resistance to insulin-mediated glucose disposal. To maintain normoglycaemia, there is compensatory pancreatic bcell hypersecretion, resulting in hyperinsulinaemia. If this pancreatic compensation fails, type 2 diabetes develops. It is thought that the hyperglycaemia that develops as a consequence of the insulin resistance may contribute to the eventual decline in b-cell function and insulin production through glucotoxicity on the b-cells. In addition to diabetes, insulin resistance is also implicated in the pathogenesis of hypertension, coronary artery disease and polycystic ovarian syndrome as a component of the metabolic syndrome. 2 Type 2 diabetes usually occurs in older adults, but there has been a large rise in incidence over the last 20 years, associated with the global epidemic of obesity, so that it now a¡ects about 4% of all UK adults. Worldwide there are currently 110 million people with diabetes, the majority of whom have type 2 diabetes; this number is predicted to double by the year 2010. In the USA between 1990 and 1998 the prevalence of diabetes increased by 33% overall but by 76% in people aged 30 -39 years. 3
Recently recognized forms of childhood diabetes Type 2 diabetes in children
In 2000 we described the ¢rst UK children with type 2 diabetes, in eight adolescent girls who were all of South Asian (Indian and Pakistani) or Arab origin. 4 All were overweight or obese according to the International Obesity Taskforce cut-o¡ lines, extrapolated to pass through a body mass index (BMI) of 25 (for overweight) and 30 (for obese) at age 18 years. 5 They presented insidiously in puberty with raised blood glucose; none developed ketoacidosis and all were initially managed with dietary therapy. All had signs of insulin resistance and a positive family history of type 2 diabetes. Type 2 diabetes had not previously been described in South Asian children but it is well established that South Asian adults are a high-risk group, with more than one in ¢ve a¡ected. 6 Our report of type 2 diabetes in UK children was not an isolated report, as cases have also been reported in the literature from Carshalton and Bristol, and a recent survey by the British Society for Paediatric Endocrinology and Diabetes (BSPED) con¢rmed the emergence of type 2 diabetes in the paediatric age group with cases reported from 18 centres across the UK. 7^9 The UK prevalence of type 2 diabetes in children is currently low (0.21 per 100 000 children under 16 years) but will almost certainly rise as clinicians become more aware of the problem and the prevalence of childhood obesity rises. 10 The emergence of type 2 diabetes in UK children has occurred 20 years after the ¢rst children were reported from North America (in 1979 in the USA in Pima Indian adolescents 11 ). Pima Indians are a native American-Indian population with an extremely high incidence of type 2 diabetes in adults: more than 40% of those over age 35 years are a¡ected. Since then, children have been identi¢ed in other parts of the USA and Canada in other native Indian populations and in African-and Hispanic-Americans. 12^14 More recently, cases have been reported worldwide, from places as diverse as Libya, New Zealand and Japan. 15^17 The case reports re£ect the global spread of childhood obesity, which began in North America in the 1970s. The majority of reported children are adolescent, obese and 80% are female. 18 Up to 90% have acanthosis nigricans, a cutaneous marker of insulin resistance. 19 Certain ethnic groups appear to be more at risk, particularly native American-Indians, Mexican-Americans, African-Americans, Aborigines, Arabs and Japanese children. This may relate to the known marked ethnic variation in insulin resistance. South Asian adults are more insulin-resistant than White Europeans at equivalent BMI and are in a high-risk group for type 2 diabetes and coronary artery disease. 20, 21 The connection between increased adiposity and insulin resistance remains unclear, but regional fat distribution appears to be more important than BMI; in South Asian adults, visceral fat and total body fat are strongly correlated with markers of insulin resistance, even at lean BMIs. 22, 23 The management of type 2 diabetes in children involves education regarding healthy lifestyles (exercise and diet), achievement of weight stabilization to maintain normal linear growth, and reduction of glycated haemoglobin (HbA) to less than 7.0% by a combination of insulin and an insulin sensitizer such as a biguanide (metformin). 24 At the recent American Diabetes Association's 62nd Annual Scienti¢c Meeting, data were presented on the long-term followup of 51 Canadian ¢rst-nation patients diagnosed with type 2 diabetes before the age of 17 years and now aged 18-33 years. Seven had died: two sudden deaths on dialysis of young women aged 25 and 31 years, two from trauma and three from unrelated illnesses. Three others were on dialysis, one became blind at the age of 26 years and one had had a toe amputation. Of 56 pregnancies in this cohort, only 35 had resulted in live births (62.5%). As can be seen from this group, the prognosis for young people developing type 2 diabetes is poor, with signi¢cant morbidity and mortality in their third and fourth decades. 25
Maturity-onset diabetes of the young (MODY)
MODY is a relatively rare form of familial diabetes characterized by a young age of onset, often before the age of 25 years, non-insulin-dependent and an autosomal-dominant mode of inheritance. 26 Several genetic subtypes of MODY have now been described, all characterized by mild fasting hyperglycaemia in otherwise well children, and have recently been reviewed. 27 The glucokinase (MODY2) gene was iden-ti¢ed ¢rst; 28 the abnormality lies in the glucosesensing mechanism of the b-cell, which does not detect capillary glucose concentrations until they are 1-2 mmol/ L higher than normal. Other gene loci were identi¢ed on chromosome 20q (MODY1) 29 and 12q (MODY3). 30 The MODY3 gene was identi¢ed as hepatocyte nuclear factor (HNF)-1a. 31 HNF-4a was identi-¢ed as MODY1. 32 HNF-1b was identi¢ed as MODY5. 33 The hepatocyte nuclear factors are transcription factors, not previously known to be involved in insulin metabolism. HNF-1a is the commonest cause of MODY in the UK, accounting for about 65% of families, with glucokinase MODY accounting for about 15%. 27 The importance of distinguishing these subtypes lies in their di¡ering prognoses and treatments. Glucokinase MODY is not associated with long-term complications, and rarely needs treatment outside of pregnancy. In contrast, HNF-1a MODY is associated with microvascular and macrovascular complications, and responds to sulphonylurea treatment. 34 The underlying pathophysiology is thought to be a progressive deterioration in b-cell function. 35 
Syndromes of insulin resistance
Mutations in the insulin receptor have been found to account for some rare syndromes of insulin resistance, but are not responsible for the insulin resistance seen in type 2 diabetes. An example is leprechaunism (Donohue syndrome), in which children present in infancy with hirsutism, acanthosis nigricans, reduced subcutaneous fat and coarse facies. 36 Insulin binding to receptors is severely decreased. Rabson-Mendenhall syndrome is another extreme form of insulin resistance, in which diabetes mellitus presents between 3 and 7 years of age, and ketoacidosis is a common cause of mortality by the second decade. The syndrome is also caused by mutations in the insulin receptor, causing defective insulin binding. 37 More than 50 insulin receptor mutations have been described, the vast majority in association with these extreme insulin-resistance syndromes. These mutations either abolish insulin receptor binding, disrupt the tyrosine kinase activity of the receptor, or interfere with the synthesis and expression of the receptor. 38 It may be that that leprechaunism, Rabson-Mendenhall syndrome and type A insulin resistance (non-obese, non-dysmorphic, severely insulin-resistant females with hirsutism, acanthosis nigricans and menstrual disturbance) represent points on a spectrum of receptor dysfunction. 39 Figure 1 shows a diagnostic approach to diabetes in children and young people. Di¡erentiation of types 1 and 2 diabetes and MODY in childhood can be di¤cult. Factors that would make a diagnosis of type 1 diabetes more likely include young age at presentation, short duration of symptoms, ketoacidosis, autoantibodies and history of weight loss. Table 1 compares the features of children with type 2 diabetes and MODY reported to the recent BSPED national survey of nontype 1 diabetes in childhood with those of the last 50 children with type 1 diabetes diagnosed at our institution between 2000 and 2001. 9 Type 2 diabetes is more likely if there is evidence of insulin resistance with acanthosis nigricans or hyperinsulinaemia. Obesity, ethnic minority origin and family history of type 2 diabetes may also indicate type 2 diabetes. Children and young people with type 2 diabetes may present with a spectrum from severe insulin de¢ciency to mild hyperglycaemia. The child may have ketonuria, ketoacidosis, or both, with signs and symptoms compatible with type 1 diabetes. Often the distinction between type 1and type 2 diabetes is not possible until months or years later, when insulin requirements decline below those of the`honeymoon' period and a non-insulin-dependent course develops. On the other hand, children with type 2 diabetes may be completely asymptomatic. In one series, 50% of children with type 2 diabetes were asymptomatic and were referred only because of glycosuria on routine analysis. 40 An autosomal-dominant family history of diabetes may suggest MODY; to date, all MODY families described in the UK are of White UK origin and demonstration of hyperinsulinaemia would make MODY unlikely. Occasionally children with MODY may not have a family history of diabetes, and some MODY patients do develop ketonuria.
Differential diagnosis

Investigations
Glucose monitoring
The World Health Organization criteria for the diagnosis of diabetes are a fasting venous plasma glucose value greater than or equal to 7.0 mmol/ L or a value greater than or equal to 11.1 mmol/ L 2 h after a glucose load. 2 If the plasma glucose concentrations are diagnostic and the child is unwell, it is appropriate to defer further investigations and commence treatment with insulin. It is safest to assume type 1 diabetes, treat with insulin and revise the diagnosis at the later date, rather than miss a diagnosis of type 1 diabetes. If a child is well, with plasma glucose concentrations that are not diagnostic of diabetes, then options for further investigations include a short period of home blood glucose monitoring. The place of the oral glucose tolerance test in children has not been established, and it is not recommended for routine use in children suspected of diabetes. If there is doubt about the type of diabetes, then further investigations are indicated.
Assessment of insulin sensitivity
The usual laboratory indication for measurement of plasma insulin is in the investigation of hypoglycaemia. It will become more likely in future that insulin measurement will be undertaken as part of the assessment of insulin resistance when there is normoglycaemia or hyperglycaemia. The gold standard test for assessment of insulin sensitivity is the euglycaemic clamp; however, the complexity of this technique limits its clinical application and simpler tests are required for clinical use. Useful investigations include fasting insulin and C-peptide concentrations with a paired glucose, in order to determine whether there is insulin insu¤ciency or insulin resistance. The American Heart Association suggests the following values for evaluating fasting plasma insulin concentrations in children: normal 515 mU/L, borderline high 15-20 mU/L, high 420 mU/L. The conversion factor to pmol/ L is 66.6, giving corresponding values of: normal, 599 pmol/L; borderline high, 99-132 pmol/ L; high, 4132 pmol/L). 41 High fasting insulin values in the face of normal glucose values indicate a degree of hyperinsulinaemia and insulin resistance. Other indices that correlate well with insulin resistance include fasting C-peptide values, proinsulin and split proinsulin. A fasting insulin/glucose ratio would help to determine whether the level of insulin is appropriate for the level of glycaemia; this can be assessed further using homeostatic model assessment (HOMA). 42, 43 HOMA analysis HOMA analysis is done using a computer program that utilizes fasting glucose and insulin or C-peptide values to model b-cell function (%B) and insulin sensitivity (%S), which are then expressed in relation to values in a`standard individual', in which they are each accorded the value 100%. Hence, values for %S less than 100% indicate a degree of insulin resistance compared to the reference population. As it compares the input values to those of a young lean reference population used to standardize the model, the glucose and hormone values at %Bˆ100 and %Sˆ100 should not be interpreted as`normal values', as other normal populations' would have %B and %S values signi¢cantly di¡erent from 100%. It is also important to note that di¡erences between assays in di¡erent centres will generate di¡erences in %B and %S. Therefore, care should be taken with direct comparisons between %B and %S values generated from di¡erent assays. As HOMA is designed to compare values in two groups or in a single group under di¡erent conditions, using the same biochemical assays for each group, it is more appropriate for population studies than for the assessment of individuals.
Assessment of insulin secretion
In a proportion of individuals with insulin resistance, the fasting insulin concentrations are normal but stimulated insulin concentrations are raised. Our own practice is to undertake insulin measurements at 0 and 30 min in a standard 75-g oral glucose tolerance test, and calculate the ratio of the 30-min increment in insulin concentration to the 30-min increment in glucose concentration. This has been shown to correlate with the ¢rst-phase insulin response in an intravenous glucose tolerance test. 44 An alternative measure is to use the 30-min insulin incremental response, which is the ratio of the 30-min increment in insulin to the 30-min glucose value. 45
Assessment of autoimmunity
Almost all children presenting with type 1 diabetes have some evidence of autoimmunity. The majority are positive for islet cell antibodies and 85% are positive for glutamic acid decarboxylase antibodies. It is more unusual for people with type 2 diabetes to have autoantibodies. 46 The BSPED survey found autoantibodies in 8% of children with type 2 diabetes. 9 It may be that these children actually have type 1 diabetes, but their obesity results in increased resistance to the action of insulin. Further studies are needed for a de¢nitive conclusion, partly because latent autoimmune diabetes was recently described in adults with type 2 diabetes. 47 These patients have islet cell autoantibodies and glutamic acid decarboxylase antibodies and manifest lower C-peptide and insulin response to glucose compared with antibody-negative patients who have type 2 diabetes mellitus.
Genetic testing for diabetes
There is no genetic test for type 1 or type 2 diabetes. However, tests are available for the common genetic subtypes of MODY. Indications for genetic testing for MODY include a positive family history for diabetes in an autosomal-dominant inheritance pattern (on one side of the family in at least two generations), and a low or absent insulin requirement 2 years after diagnosis of diabetes. Further information can be obtained from the molecular diagnostics laboratory in Exeter. 48
Conclusions
Type 1 diabetes remains the most common form of diabetes in children, and must be considered ¢rst in any child presenting with a raised plasma glucose. Type 2 diabetes has now emerged in the UK child population, associated with the rising prevalence of childhood obesity. The ¢rst children to be a¡ected appear to be those from ethnic minorities, who may have additional susceptibility factors such as a family history of type 2 diabetes. Genetic subtypes of diabetes include MODY, which usually involves mild hyperglycaemia and a positive family history down one side of the family. Di¡erential diagnosis may be di¤cult in overweight teenagers, and sometimes the diagnosis may have to be revised after 3 months of insulin treatment. The clinical chemistry laboratory can help by the assessment of fasting insulin concentrations and C-peptide. The demonstration of high fasting insulin concentrations in the presence of normoglycaemia is indicative of insulin resistance. There is an urgent need to develop normal ranges for insulin and Cpeptide for pubertal boys and girls from ethnic minorities. The place of autoantibody testing in diabetes has not yet been de¢ned. Genetic testing may be available for some types of MODY; further information may be obtained from the website. 48 Diabetes UK have now set up a register of children with diabetes throughout the UK. All diabetes centres submit annual reports to this register, so it is likely to give information on changes in prevalence of type 2 diabetes in children. There is an urgent need to characterize type 2 diabetes in childhood in terms of insulin secretion, tissue sensitivity and autoantibody status. We need epidemiological studies of long-term outcome in terms of complications. At present there are no clinical guidelines for the management of type 2 diabetes in children; draft guidelines for the UK are available on the British Society for Paediatric Endocrinology and Diabetes website. 49 There is no doubt that, if the current trends for increased childhood obesity continue and follow the pattern seen in North America, the UK will develop similar rates of type 2 diabetes in children over the next 10 -15 years (up to 45% of all new cases of diabetes 50 ). The best way to prevent this scenario is to develop a public health strategy to encourage healthier lifestyles. This could include initiatives to get children to walk to school, more time in the national curriculum for sport, and provision of playing ¢elds and sports facilities. In addition, banning advertising directed at children, removing ¢zzy drink dispensing machines from schools and adding value-added tax (VAT) to takeaway hot meals. Diabetes in childhood has now become a diagnostic as well as a management challenge, and long-term prevention will involve a change in lifestyle for the whole of our society.
